Company Overview and News

20
UPDATE 1-Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

2018-06-06 reuters
BOSTON (Reuters) - Danish drugmaker Lundbeck (LUN.CO) said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.
PFZ JAZZ UTHR 500680 PFE PFIZER

1231
20 Best S&P 500 Stocks to Buy for the Second Half | InvestorPlace

2018-06-06 investorplace
The S&P 500 is one of the oldest and most widely used market index for U.S. stocks. The index — which does change over time — consists of 500 large-cap stocks, chosen to provide a diversified profile of the U.S. stock market — and the U.S. economy. S&P 500 stocks must have a minimum market capitalization (currently $6.1 billion)
LRCX STZ.B XOM TEVA AA.PRB WMT CRM DLTR AMZN VIAB AMAT CELG AVGO AA MMM UPS VRX TYT STZ CBS.WD PFIZER BP GT JNJ 7203 NVS MSFT CPV QCOM PFE AEUA APC APA MTSI PG TM TEVVF NFLX ADBE BAC COO AAI MKC AAPL INTC DAL ORCL DIS LUV IBM CBS VIA PFZ F CELGZ CBS.A FDX BIG TOYOF HMC PEP JPM TEVJF AA.PR OCLCF KHC DG MNK BRCM 500680

16
Pfizer Drops $600 Million in Its Venture Capital Arm

2018-06-06 247wallst
Pfizer Inc. (NYSE: PFE) shares were up marginally on Wednesday after the pharmaceutical giant announced that it would be committing over half a billion dollars to its venture capital arm.
PFZ 500680 PFE PFIZER

16
6 Months After Pfizer Cuts Neuroscience Development, Adds $600 Million to Venture Arm with 25% Sl...

2018-06-06 biospace
In late January, Pfizer Inc. abandoned its research and development of new neuroscience programs. Along with the news came 300 job cuts. It was terminating eight different projects. Two were in Phase II while six others were in Phase I. The two Phase II projects were PF-06372865 for epilepsy and PF-06649751 for Parkinson’s disease. Four of the Phase I projected targeted Alzheimer’s disease. The other two Phase I candidates were for a cognitive disorder and schizophrenia.
PFZ 500680 PFE PFIZER

16
Pfizer pumps US$600 million into venture capital arm

2018-06-06 channelnewsasia
Pfizer Inc said on Wednesday it planned to invest US$600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.
PFZ 500680 PFE PFIZER

16
Pfizer pumps $600 million into venture capital arm

2018-06-06 reuters
(Reuters) - Pfizer Inc (PFE.N) said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.
PFZ 500680 PFE PFIZER

106
Alibaba incubates new risk for investors

2018-06-05 thestar.com.my
BEIJING: Jack Ma just sowed the seed of another decacorn – a startup worth more than US$10bil – on the Hong Kong stock exchange.
SBMFF PFZ MS.PRE MS.PRF SBHMY MS.PRG MS.PRA PFIZER 1177 BABA MS.PRI MS.PRK MS 500680 PFE ALBHF

16
Some cancer patients can skip costly chemo — without harming survival rates - MarketWatch

2018-06-04 marketwatch
The average monthly price of oncology drugs in the U.S. has more than doubled since 2006 to $15,535 in 2015.
PFZ 500680 PFE PFIZER

31
This Fungus Could Help Cure Cancer - Bloomberg

2018-06-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ RHHVF RHHBY 500680 PFE PFIZER RHHBF

103
RPT-U.S. FDA wants to shorten new drug monopolies to cut costs

2018-06-04 reuters
CHICAGO, June 3 (Reuters) - In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

187
Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside.
LZAGY MKGAF PFZ C O6Z MS.PRE CRSP MS.PRF MS.PRG MS.PRA PFIZER BAC CDMO MS.PRI MKGAY MS.PRK 4502 MS ORGS 500680 PFE WXXWY LZAGF

102
U.S. FDA wants to shorten new drug monopolies to cut costs

2018-06-03 reuters
CHICAGO (Reuters) - In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

102
FDA wants to shorten new drug monopolies to cut costs

2018-06-03 channelnewsasia
In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines.
PFZ REGN AMGN GILD 500680 PFE PFIZER

16
Texas high court rules state must reveal supplier of execution drugs

2018-06-01 reuters
AUSTIN, Texas (Reuters) - Texas must reveal the source of the drugs it uses for executions, its Supreme Court affirmed on Friday, rejecting the state’s arguments that doing so could lead to physical harm of the supplier and impede lethal injections.
PFZ 500680 PFE PFIZER

154
Pfizer Inc. Stock Desperately Needs a Viagra-Like Boost

2018-05-31 investorplace
Pfizer Inc. (NYSE:PFE) is a prime example of a company working a sweat but never actually getting anywhere. The spread between the highs and lows for PFE stock this year is nearly 18%, which suggests some direction. Yet since January’s opening bell up to the May 29 session, shares are exactly at parity.
MYL PFZ TEVJF MRK TEVA TEVVF 500680 PFE GSK PFIZER

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

11h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...